Recommendations from the AML molecular MRD expert advisory board

Affiliations

• ¹ UK NEQAS for Leucocyte Immunophenotyping, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. stuart.scott@ukneqasli.co.uk.
• ² Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK. stuart.scott@ukneqasli.co.uk.
• ³ Molecular and Cell Biology, National Measurement Laboratory, LGC, Teddington, UK.
• ⁴ Department of Haematology, Guy's International Centre of Excellence in Myeloid Disorders, Guy's and St Thomas NHS Foundation Trust, London, UK.
• ⁵ Department of Medical and Molecular Genetics, King's College, London, UK.
• ⁶ University Hospital Carl Gustav Carus, Dresden University of Technology, Dresden, Germany.
• ⁷ AgenDix, Applied Molecular Diagnostics, GmbH, Dresden, Germany.
• ⁸ Faculty of Medicine, University of Southampton, Southampton, UK.
• ⁹ Wessex Genomics Laboratory Service, Salisbury District Hospital, Salisbury, UK.
• ¹⁰ Diagnostics R&D, Medicines and Healthcare Products Regulatory Agency (MHRA), Potters Bar, UK.
• ¹¹ Cancer Genetics, Guy's Hospital, Synnovis, London, UK.
• ¹² Laboratory of Myeloid Malignancies, National Heart, Lung, and Blood Institute, Bethesda, MD, USA.
• ¹³ Translational Science & Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
• ¹⁴ Digital Biology Group, Bio-Rad Laboratories, Pleasanton, CA, USA.
• ¹⁵ Translational Science and Precision Diagnostics, QIAGEN, Courtaboeuf, France.
• ¹⁶ Horizon Discovery, Diagnostic Reference Standards, Cambridge, UK.
• ¹⁷ AccuGenomics, Inc., Wilmington, NC, USA.
• ¹⁸ Clinical NGS and Oncology Division, Thermo Fisher, Paisley, UK.
• ¹⁹ UK NEQAS for Leucocyte Immunophenotyping, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.